Radiotherapy & Oncology
Volume 95, Issue 3 , Pages 308-311 , June 2010

Chemoreirradiation for recurrent salivary gland malignancies

  • Aaron W. Pederson

      Affiliations

    • Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA
    • ,
  • Daniel J. Haraf

      Affiliations

    • Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA
    • Cancer Research Center, University of Chicago, Chicago, IL, USA
    • ,
  • Elizabeth A. Blair

      Affiliations

    • Cancer Research Center, University of Chicago, Chicago, IL, USA
    • Section of Otolaryngology/Head and Neck Surgery, University of Chicago, Chicago, IL, USA
    • ,
  • Kerstin M. Stenson

      Affiliations

    • Cancer Research Center, University of Chicago, Chicago, IL, USA
    • Section of Otolaryngology/Head and Neck Surgery, University of Chicago, Chicago, IL, USA
    • ,
  • Mary-Ellyn Witt

      Affiliations

    • Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA
    • ,
  • Everett E. Vokes

      Affiliations

    • Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA
    • Cancer Research Center, University of Chicago, Chicago, IL, USA
    • Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA
    • ,
  • Joseph K. Salama

      Affiliations

    • Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA
    • Cancer Research Center, University of Chicago, Chicago, IL, USA
    • Ludwig Center of Metastases, University of Chicago, Chicago, IL, USA
    • Corresponding Author InformationCorresponding author at: Department of Radiation and Cellular Oncology, University of Chicago, 5758 S. Maryland Ave., MC 9006, Chicago, IL 60637, USA.

Received 8 June 2009 ,Revised 23 February 2010 ,Accepted 7 March 2010.

References 

  1. Armstrong JG, Harrison LB, Spiro RH, Fass DE, Strong EW, Fuks ZY. Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy. Arch Otolaryngol Head Neck Surg. 1990;116:290–293
  2. Laramore GE, Krall JM, Griffin TW, et al. Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Int J Radiat Oncol Biol Phys. 1993;27:235–240
  3. Terhaard CH. Postoperative and primary radiotherapy for salivary gland carcinomas: indications, techniques, and results. Int J Radiat Oncol Biol Phys. 2007;69:S52–S55
  4. Fu KK, Leibel SA, Levine ML, Friedlander LM, Boles R, Phillips TL. Carcinoma of the major and minor salivary glands: analysis of treatment results and sites and causes of failures. Cancer. 1977;40:2882–2890
  5. Harrison LB, Armstrong JG, Spiro RH, Fass DE, Strong EW. Postoperative radiation therapy for major salivary gland malignancies. J Surg Oncol. 1990;45:52–55
  6. Chen AM, Bucci MK, Quivey JM, Garcia J, Eisele DW, Fu KK. Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas. Int J Radiat Oncol Biol Phys. 2006;66:1044–1050
  7. Surakanti SG, Agulnik M. Salivary gland malignancies: the role for chemotherapy and molecular targeted agents. Semin Oncol. 2008;35:309–319
  8. Salama JK, Vokes EE, Chmura SJ, et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2006;64:382–391
  9. Haraf DJ, Vokes EE, Weichselbaum RR, Panje WR. Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer. Laryngoscope. 1992;102:630–636
  10. Salama JK, Haraf DJ, Stenson K, Milano MT, Witt ME, Vokes EE, et al. Study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer. Cancer J. 2005;11:140–146
  11. Milano MT, Haraf DJ, Stenson KM, et al. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. Clin Cancer Res. 2004;10:4922–4932
  12. Vokes EE, Haraf DJ, Brockstein BE, Weichselbaum RR. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer. Semin Radiat Oncol. 1999;9:70–76
  13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:547–581
  14. Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol. 2007;4:156–171
  15. Salama JK, Seiwert TY, Vokes EE. Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol. 2007;25:4118–4126
  16. Hehr T, Classen J, Belka C, et al. Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: a prospective phase I/II trial. Int J Radiat Oncol Biol Phys. 2005;61:1423–1431
  17. Machtay M, Rosenthal DI, Chalian AA, et al. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;59:72–77
  18. Nagar YS, Singh S, Datta NR. Chemo-reirradiation in persistent/recurrent head and neck cancers. Jpn J Clin Oncol. 2004;34:61–68
  19. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med. 2001;345:1890–1900
  20. Pederson A, Salama J, Haraf D, Witt M, Stenson K, Vokes E, et al. Chemoradiotherapy for locoregionally advanced and high risk salivary gland malignancies. Poster session presented at: 7th International Conference on Head and Neck Cancer; 2008, Jul 19–23; San Francisco, CA.
  21. Dreyfuss AI, Clark JR, Fallon BG, Posner MR, Norris CM, Miller D. Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer. 1987;60:2869–2872
  22. Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol. 2006;24:2673–2678
  23. Licitra L, Cavina R, Grandi C, et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol. 1996;7:640–642
  24. Dimery IW, Legha SS, Shirinian M, Hong WK. Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. J Clin Oncol. 1990;8:1056–1062
  25. Douglas JG, Koh WJ, Austin-Seymour M, Laramore GE. Treatment of salivary gland neoplasms with fast neutron radiotherapy. Arch Otolaryngol Head Neck Surg. 2003;129:944–948
  26. Argiris A, Haraf DJ, Kies MS, Vokes EE. Intensive concurrent chemoradiotherapy for head and neck cancer with 5-fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. Oncologist. 2003;8:350–360
  27. Agulnik M, Cohen EW, Cohen RB, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non-adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol. 2007;25:3978–3984
  28. Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003;39:724–727
  29. Locati LD, Rinaldi G, Bossi P, et al. Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer. Oral Oncol. 2005;41:97–98

PII: S0167-8140(10)00157-X

doi: 10.1016/j.radonc.2010.03.006

Radiotherapy & Oncology
Volume 95, Issue 3 , Pages 308-311 , June 2010

Article Tools

* Image Usage & Resolution